Glycorex Transplantation (DB:O33) - Stock Price, News & Analysis

O33 Stock Overview

A medical technology company, engages in the development, production, and sale of products for use in organ transplantation.

About the company

O33 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Earnings have declined by 50.9% per year over past 5 years

Does not have a meaningful market cap (€151M)

+ 1 more risk

Glycorex Transplantation AB (publ) Competitors

aap Implantate

XTRA:AAQ1

€13.0m

Geratherm Medical

XTRA:GME

€21.3m

Audientes

DB:AUG

€6.9m

NanoRepro

XTRA:NN6

€22.8m

Price History & Performance

Summary of all time highs, changes and price drops for Glycorex Transplantation
Historical stock prices
Current Share Price	SEK 0.16
52 Week High	SEK 0.18
52 Week Low	SEK 0.089
Beta	0.14
11 Month Change	54.63%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	54.63%

Recent updates

Shareholder Returns

	O33	DE Medical Equipment	DE Market
7D	39.0%	12.4%	3.1%
1Y	n/a	9.5%	13.3%

Return vs Industry: Insufficient data to determine how O33 performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how O33 performed against the German Market.

Price Volatility

Is O33's price volatile compared to industry and market?
O33 volatility
O33 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.1%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.4%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: O33's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine O33's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1996	20	Johan Nilsson	www.glycorex.se

Glycorex Transplantation AB (publ), a medical technology company, engages in the development, production, and sale of products for use in organ transplantation. It develops a molecular level nanosurgical technology that specifically selects and removes antibodies in the blood focusing areas within transplants, blood transfusion, and blood products, as well as autoimmune disease. The company’s principal product is Glycosorb-ABO, which facilitates the transplantation of organs over the blood group barriers that is used for the blood group-incompatible kidney, liver, heart, lungs, pancreatic, and stem cells transplantation procedures.

Glycorex Transplantation AB (publ) Fundamentals Summary

How do Glycorex Transplantation's earnings and revenue compare to its market cap?
O33 fundamental statistics
Market cap	€13.32m
Earnings (TTM)	-€2.46m
Revenue (TTM)	€2.76m

5.2x

P/S Ratio

-5.8x

P/E Ratio

Is O33 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
O33 income statement (TTM)
Revenue	SEK 31.22m
Cost of Revenue	SEK 5.50m
Gross Profit	SEK 25.72m
Other Expenses	SEK 53.55m
Earnings	-SEK 27.83m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 28, 2024

Earnings per share (EPS)	-0.38
Gross Margin	82.39%
Net Profit Margin	-89.14%
Debt/Equity Ratio	1.9%

How did O33 perform over the long term?

See historical performance and comparison

Glycorex Transplantation DB:O33 Stock Report